Li L, Weintraub L, Concepcion W, Martin J P, Miller K, Salvatierra O, Sarwal M M
Division of Pediatric Nephrology, Department of Pediatrics, Stanford University School of Medicine, Stanford, CA 94305-5208, USA.
Pediatr Transplant. 2008 Sep;12(6):701-7. doi: 10.1111/j.1399-3046.2007.00884.x. Epub 2007 Dec 26.
With the increasing adoption of steroid-sparing immunosuppression protocols in renal transplantation, it is important to evaluate any adverse effects of steroid avoidance on graft function. Early graft function, measured by CrCl was retrospectively studied in 158 consecutive pediatric renal transplant recipients from 1996 to 2005, receiving either steroid-free or steroid-based immunosuppression. Patients receiving steroid-free immunosuppression vs. steroid-based immunosuppression had no difference change in CrCl (DeltaCrCl) in the first week post-transplantation (p = 0.12). When stratified by corticosteroid usage, patients with higher tacrolimus trough levels (> or =14 ng/mL) had slower graft function recovery in the first week post-transplantation than those with lower tacrolimus trough levels (p = 0.008) in the steroid-free group only. Despite initial slower graft function recovery in this subgroup, there was no negative impact on graft function in the steroid-free group; in fact steroid-free patients trended towards better CrCl at six months (p = 0.047) and 12 months (p < 0.001) post-transplant than the steroid-based group. With the improved immunological outcomes with steroid avoidance, close surveillance should be performed of tacrolimus levels to avoid levels >14 ng/mL. In patients with slow recovery of early graft function, short-term perioperative steroids may be considered.
随着肾移植中减少类固醇免疫抑制方案的日益采用,评估避免使用类固醇对移植物功能的任何不良影响非常重要。对1996年至2005年期间连续158例接受无类固醇或基于类固醇免疫抑制的儿科肾移植受者,通过肌酐清除率(CrCl)来衡量的早期移植物功能进行了回顾性研究。接受无类固醇免疫抑制与接受基于类固醇免疫抑制的患者在移植后第一周的CrCl变化(DeltaCrCl)无差异(p = 0.12)。按皮质类固醇使用情况分层时,仅在无类固醇组中,他克莫司谷浓度较高(≥14 ng/mL)的患者在移植后第一周的移植物功能恢复比他克莫司谷浓度较低的患者慢(p = 0.008)。尽管该亚组最初移植物功能恢复较慢,但无类固醇组对移植物功能没有负面影响;事实上,无类固醇患者在移植后6个月(p = 0.047)和12个月(p < 0.001)时的CrCl有优于基于类固醇组的趋势。随着避免使用类固醇带来的免疫结果改善,应密切监测他克莫司水平以避免超过14 ng/mL。对于早期移植物功能恢复缓慢的患者,可考虑在围手术期短期使用类固醇。